AA
REGN icon

Apriem Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Apriem Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.3M Sell
8,156
-428
-5% -$328K 0.6% 37
2025
Q4 		$6.63M Sell
8,584
-64
-0.7% -$43.5K 0.61% 37
2025
Q3 		$4.86M Sell
8,648
-469
-5% -$265K 0.46% 42
2025
Q2 		$4.79M Sell
9,117
-3,319
-27% -$1.85M 0.51% 42
2025
Q1 		$7.89M Sell
12,436
-2,058
-14% -$1.42M 0.92% 32
2024
Q4 		$10.3M Sell
14,494
-1,033
-7% -$867K 1.18% 25
2024
Q3 		$16.3M Sell
15,527
-806
-5% -$897K 1.91% 13
2024
Q2 		$17.2M Sell
16,333
-4,390
-21% -$4.26M 2.1% 9
2024
Q1 		$19.9M Sell
20,723
-3,095
-13% -$2.94M 2.51% 8
2023
Q4 		$20.9M Sell
23,818
-1,099
-4% -$905K 2.79% 9
2023
Q3 		$20.5M Sell
24,917
-685
-3% -$538K 3% 8
2023
Q2 		$18.4M Sell
25,602
-505
-2% -$389K 2.76% 8
2023
Q1 		$21.5M Sell
26,107
-5,265
-17% -$3.97M 3.43% 7
2022
Q4 		$22.6M Sell
31,372
-876
-3% -$646K 3.92% 6
2022
Q3 		$22.2M Buy
32,248
+28
+0.1% +$17.6K 4.01% 6
2022
Q2 		$19M Buy
32,220
+82
+0.3% +$53.3K 3.28% 8
2022
Q1 		$22.4M Buy
32,138
+386
+1% +$244K 3.29% 5
2021
Q4 		$20.1M Buy
+31,752
New +$19.5M 2.84% 10
2017
Q2 		– Sell
-25
Closed -$10K – 448
2017
Q1 		$10K Hold
25
– – ﹤0.01% 421
2016
Q4 		$9K Sell
25
-20
-44% -$7.61K ﹤0.01% 451
2016
Q3 		$18K Hold
45
– – 0.01% 344
2016
Q2 		$16K Hold
45
– – 0.01% 366
2016
Q1 		$16K Hold
45
– – 0.01% 330
2015
Q4 		$24K Hold
45
– – 0.01% 275
2015
Q3 		$21K Hold
45
– – 0.01% 290
2015
Q2 		$23K Buy
45
+20
+80% +$9.76K 0.01% 303
2015
Q1 		$11K Buy
+25
New +$10.6K ﹤0.01% 405

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Apriem Advisors's REGN Position: Q1 2026 in Review

Apriem Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 5% in Q1 2026, selling an estimated $328K and leaving 8,156 shares worth $6.3M. The position accounts for 0.6% of the portfolio, ranked #37.

Apriem Advisors first reported a position in REGN in Q1 2015 and has held it in 27 quarters since. The position peaked at $22.6M in Q4 2022. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Apriem Advisors held 8,156 shares of Regeneron Pharmaceuticals worth $6.3M as of Q1 2026.
  • Apriem Advisors sold 428 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $328K.
  • Regeneron Pharmaceuticals made up 0.6% of Apriem Advisors's portfolio in Q1 2026, its #37 holding.
  • Apriem Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2015 and has held it in 27 quarters since.
  • Apriem Advisors's Regeneron Pharmaceuticals position peaked at $22.6M in Q4 2022.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Apriem Advisors's 13F filing for Q1 2026, filed 15 May 2026.